||This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: the content/scope are not encyclopedic for an important anesthetic, and sources are often primary/lacking. (August 2014)|
||This article needs attention from an expert in Medicine. The specific problem is: the article is limited in scope (note current outline), and lacks standard secondary anesthesiology medical refs. (August 2014)|
|Systematic (IUPAC) name|
|Trade names||Sojourn, Ultane, Sevorane|
|Mol. mass||200.055 g/mol|
|(what is this?)|
Sevoflurane (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane; synonym, fluoromethyl hexafluoroisopropyl ether), is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. This anesthetic's name derives from having its from having seven fluorine atoms in its substituents, alongside a standard suffix for such agents.
It is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine. Together with desflurane, sevoflurne is replacing isoflurane and halothane in modern anesthesiology. It is often administered in a mixture of nitrous oxide and oxygen.
After desflurane, it is the volatile anesthetic with the fastest onset and offset. Though desflurane has the lowest blood/gas coefficient of the currently used volatile anesthetics, sevoflurane is the preferred agent for mask induction due to its lesser irritation to mucous membranes.
Sevoflurane "has an excellent safety record", but is under review for potential neurotoxicity especially relevant to administration in infants and children, and rare case reports akin to halothane hepatitis have made clear that low frequency liver injury may occur.
Sevoflurane was discovered by Ross Terrell. First reports on the use of sevoflurane appeared in the literature in 1971; it was introduced into clinical practice initially in Japan in 1990. The rights for sevoflurane in the US and other countries were held by Abbott Laboratories; it is now available as a generic drug.[when?]
Toxic breakdown products
||This section contains information of unclear or questionable importance or relevance to the article's subject matter. Please help improve this article by clarifying or removing superfluous information. (August 2014)|
||This section needs more medical references for verification or relies too heavily on primary sources. (August 2014)|
||This section may contain an excessive amount of intricate detail that may only interest a specific audience. (August 2014)|
Studies examining a current significant health concern, anesthetic-induced neurotoxicity (including with sevoflurane, and especially with children and infants) are "fraught with confounders, and many are underpowered statistically", and so are argued to need "further data... to either support or refute the potential connection".
In vitro studies related to this and other important drug safety questions have focused on chemical degradation products, and on metabolic products relevant to sevoflurane administration. Sevoflurane forms a range of degradation products, compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether][non-primary source needed] also called PIFE (pentafluoroisopropenyl fluoromethyl ether) and Compound B [1,1,1,3,3-pentafluoro-2-(fluoromethoxy)-3-methoxypropane],[non-primary source needed] also called PMFE (pentafluoromethoxy isopropyl fluoromethyl ether) on contact with the soda lime in a rebreathing apparatus, which absorbs exhaled carbon dioxide, especially at higher temperatures and when the soda lime is desiccated.[excessive detail?] Compound A is formed by an elimination reaction which is likely to be the E2 reaction as for an E1 reaction a carbocation centred on a primary carbon bearing two fluorine atoms would have to form.[excessive detail?] Compound A reacts with methanol to form compound B by nucelophilic attack on the difluoroalkene group in compound A; a further elimination reaction forms compounds C, D and E.[excessive detail?][non-primary source needed] Hydrofluoric acid is formed in the same reaction as compound A, but as soda-lime is alkaline and contains calcium the hydrogen fluoride is likely to converted into insoluble calcium fluoride.[excessive detail?] Compound A has been shown to cause renal necrosis in rats.
Compound A reacts with the thiol groups in glutathione to form S-[2-(fluoromethoxy)-1,1,3,3,3-pentafluoropropyl]-L-cysteine, which then undergoes an enzymic reaction to form ammonium ions, pyruvate and 2-(fluoromethoxy)-1,1,3,3,3-pentafluoropropanethiolate; this ultimate fluorinated product is then converted to 2-(fluoromethoxy)-3,3,3-trifluorothiopropanoyl fluoride, an electrophile that can react with tissues, causing damage.[non-primary source needed]
In humans, direct histological evidence of renal toxicity has not been demonstrated, although there is dose-related proteinuria, glycosuria and enzymuria. During low-flow anaesthesia, when the lower fresh gas flow leads to decreased flushing of the circuit and increased temperature of the soda lime, compound A may build up to clinically significant levels, although there have never been any reports of adverse events in humans.
Sevoflurane also reacts with hydroxide anions to form fluoride anions and ((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)methanol, the ((1,1,1,3,3,3-hexafluoropropan-2-yl)oxy)methanol (a hemiacetal) breaks down to form formaldehyde and 1,1,1,3,3,3-hexafluoropropan-2-ol.[relevant? ] The formaldehyde forms formic acid and methanol in a Cannizzaro reaction; the methanol then reacts to form compound B.[relevant? ]
As a result, sevoflurane is sometimes administered with a minimum fresh gas flow of 2 liters per minute, making it a relatively expensive choice for maintaining general anesthesia. Only two countries currently have recommended minimum flow rates of 2L/min; Canada and Australia. Recent generic competition in select markets has also significantly lowered the unit cost of sevoflurane, making it more cost effective.
Concern regarding the safety of anaesthesia is especially acute with regard to children and infants, where preclinical evidence from relevant animal models suggest that common clinically important agents, including sevoflurane, may be neurotoxic to the developing brain, and so cause neurobehavioural abnormalities in the long term; two large-scale clinical studies (PANDA and GAS) were ongoing as of 2010, in hope of supplying "significant [further] information" on neurodevelopmental effects of general anaesthesia in infants and young children, including where sevoflurane is used.
Sevoflurane has been implicated in neuronal degeneration in infant mice. This activity is thought to occur via blockade of NMDA receptors or hyperactivity of GABA neurotransmission. In one study, the researchers showed exposure of infant mice to inhaled sevoflurane resulted in learning deficits and abnormal social behaviour.
|Boiling point:||58.6 °C||(at 101.325 kPa)|
|Density:||1.517–1.522 g/cm³||(at 20 °C)|
|MAC :||2.1 vol %|
|Molecular weight:||200 u|
|Vapor pressure:||157 mmHg (22.9 kPa)||(at 20 °C)|
|197 mmHg (26.3 kPa)||(at 25 °C)|
|317 mmHg (42.3 kPa)||(at 36 °C)|
|Blood:Gas partition coefficient:||0.68|
|Oil:Gas partition coefficient:||47|
- Livertox: Clinical and Research Information on Drug-Induced Liver Injury (2014) "Drug Record: Sevoflurane", U.S. National Library of Medicine, 2 July 2014 update, see , accessed 15 August, 2014.
- Sakai EM, Connolly LA, Klauck JA (December 2005). "Inhalation anesthesiology and volatile liquid anesthetics: focus on isoflurane, desflurane, and sevoflurane". Pharmacotherapy 25 (12): 1773–88. doi:10.1592/phco.2005.25.12.1773. PMID 16305297.
- Burns, William; Edmond I Eger II (August 2011). "Ross C. Terrell, PhD, an Anesthetic Pioneer". Anesth. Analg. 2 113 (113): 387–9. doi:10.1213/ane.0b013e3182222b8a.
- P. Vlisides P & Z. Xie (2012) Neurotoxicity of general anesthetics: an update., Curr Pharm Design, 18(38):6232-40, see , accessed 15 August 2015.
- Stabernack CR, Eger EI 2nd, Warnken UH, Förster H, Hanks DK, Ferrell LD (2003). "Sevoflurane degradation by carbon dioxide absorbents may produce more than one compound nephrotoxic in rats". Can J Anaesth 50 (3): 249–52. doi:10.1007/BF03017793. PMID 12620947.
- Schmidt, R.; Roeder, M.; Oeckler, O.; Simon, A.; Schurig, V. (2000). "Separation and absolute configuration of the enantiomers of a degradation product of the new inhalation anesthetic sevoflurane". Chirality 12 (10): 751–5. doi:10.1002/1520-636X(2000)12:10<751::AID-CHIR8>3.0.CO;2-H. PMID 11054834.
- J.A. Ruzicka and M.T. Baker, Journal of Fluorine Chemistry, 1995, volume 71, issue 1, pages 55-58
- R.A. Iyer, R.B. Baggs and M.W. Anders, Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats, J. Pharmacol. Exper. Therap., 1997, 283, 1544-1551
- L. Sun (2010) Early childhood general anaesthesia exposure and neurocognitive development, Br J Anaesth. 105 Suppl 1:i61-8, DOI 10.1093/bja/aeq302, see , accessed 15 August 2015.
- Satomoto M, Satoh Y, Terui K, et al. (March 2009). "Neonatal exposure to sevoflurane induces abnormal social behaviors and deficits in fear conditioning in mice". Anesthesiology 110 (3): 628–37. doi:10.1097/ALN.0b013e3181974fa2. PMID 19212262.
- Wei GH (Jan 2014). "The common anesthetic, sevoflurane, induces apoptosis in A549 lung alveolar epithelial cells". J Mol Med Rep 9 (1): 197–203. doi:10.3892/mmr.2013.1806. PMID 24248633.
- Kim JK (Feb 2014). "Relationship of bispectral index to minimum alveolar concentration during isoflurane, sevoflurane or desflurane anaesthesia.". J Int Med Res 42 (1): 130–7. doi:10.1177/0300060513505525. PMID 24366495.
- Kreuer S (Oct 2009). "Comparative pharmacodynamic modeling of desflurane, sevoflurane and isoflurane.". J Clin Monit Comput. 23 (8). doi:10.1007/s10877-009-9196-6. PMID 19711188.
- Patel SS, Goa KL (April 1996). "Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia". Drugs 51 (4): 658–700. doi:10.2165/00003495-199651040-00009. PMID 8706599.
"Erratum". Drugs 52 (2): 253. August 1996.
- Wallin, Richard F., Regan, Bernard M., Napoli, Martha D., Stern, Ivan j. (Nov–Dec 1975). "Sevoflurane: A New Inhalational Anesthetic Agent". Anesthesia and Analgesia 54 (6): 758–766. doi:10.1213/00000539-197511000-00021.